Differing Coagulation Profiles of Patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2014 Oct 2

PMID 25271000

Citations 13

Authors

Maeve P Crowley

Maeve P Crowely

Shane Quinn

Eoin Coleman

Joseph A Eustace

Oonagh M Gilligan

Susan I OShea

Susan I O Shea

Affiliations

Soon will be listed here.

Abstract

The link between myeloma and thrombosis is well established. Monoclonal gammopathy of undetermined significance (MGUS) has also been associated with an increased risk of thrombosis. It was recently demonstrated that patients with myeloma display changes in thromboelastometry that may indicate a prothrombotic state. There is little data with regard to changes in thromboelastography in patients with myeloma or MGUS. The aim of this study was to investigate the differing coagulation profiles of patients of patients with myeloma and MGUS by means of conventional coagulation tests and thromboelastography. Blood was taken by direct venepuncture from patients with myeloma, MGUS and normal controls. Routine coagulation tests were performed in an accredited hospital laboratory. Thromboelastography (TEG(®)) was performed as per the manufacturer's protocol. Eight patients were recruited in each group. Patients with myeloma had a significantly lower mean haemoglobin level than patients with MGUS or normal controls (p < 0.001). Patients with myeloma had a significantly more prolonged mean prothrombin time than normal controls (p = 0.018) but not patients with MGUS. Patients with myeloma had significantly higher median D-dimer levels than normal controls (p = 0.025), as did patients with MGUS (p = 0.017). Patients with myeloma had a significantly higher mean factor VIII level than normal controls (p = 0.009) and there was a non-significant trend towards patients with MGUS having higher factor VIII levels than normal controls (p = 0.059). There was no significant difference in thromboelastographic parameters between the three groups. Patients with MGUS appear to have a distinct coagulation profile which is intermediate between patients with myeloma and normal controls.

Citing Articles

Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights.

Tentolouris A, Ntanasis-Stathopoulos I, Gavriatopoulou M, Andreadou I, Terpos E J Cardiovasc Dev Dis. 2023; 10(12).

PMID: 38132652 PMC: 10743961. DOI: 10.3390/jcdd10120484.

Monoclonal Gammopathy of Thrombotic Significance.

Gkalea V, Fotiou D, Dimopoulos M, Kastritis E Cancers (Basel). 2023; 15(2).

PMID: 36672429 PMC: 9856365. DOI: 10.3390/cancers15020480.

Analysis of Coagulation Abnormality in Patients with Multiple Myeloma and Its Clinical Significance.

Pan P, Liu J Evid Based Complement Alternat Med. 2022; 2022:5120967.

PMID: 35769157 PMC: 9236763. DOI: 10.1155/2022/5120967.

The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.

Comerford C, Glavey S, Quinn J, OSullivan J J Thromb Haemost. 2022; 20(8):1766-1777.

PMID: 35644028 PMC: 9546473. DOI: 10.1111/jth.15773.

Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release.

Gidaro A, Manetti R, Delitala A, Soloski M, Deliliers G, Castro D J Clin Med. 2022; 11(10).

PMID: 35628848 PMC: 9143530. DOI: 10.3390/jcm11102720.

References

Ay C, Dunkler D, Marosi C, Chiriac A, Vormittag R, Simanek R . Prediction of venous thromboembolism in cancer patients. Blood. 2010; 116(24):5377-82. DOI: 10.1182/blood-2010-02-270116. View

Rajkumar S, Leong T, Roche P, Fonseca R, Dispenzieri A, Lacy M . Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000; 6(8):3111-6. View

Khorana A, Kuderer N, Culakova E, Lyman G, Francis C . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902-7. PMC: 2384124. DOI: 10.1182/blood-2007-10-116327. View

Holmberg L, Nilsson I . AHF related protein in clinical praxis. Scand J Haematol. 1974; 12(3):221-31. DOI: 10.1111/j.1600-0609.1974.tb00202.x. View

Minnema M, Fijnheer R, de Groot P, Lokhorst H . Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 2003; 1(3):445-9. DOI: 10.1046/j.1538-7836.2003.00083.x. View

Rickles F, Shoji M, Abe K . The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol. 2001; 73(2):145-50. DOI: 10.1007/BF02981930. View

Lopez-Pedrera C, Barbarroja N, Dorado G, Siendones E, Velasco F . Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia. 2006; 20(8):1331-40. DOI: 10.1038/sj.leu.2404264. View

Kopitsky R, SWITZER M, Williams R, McKee P . The basis for the increase in factor VIII procoagulant activity during exercise. Thromb Haemost. 1983; 49(1):53-7. View

Trelinski J, Misiewicz M, Robak M, Smolewski P, Chojnowski K . Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thromb Res. 2014; 133(4):667-70. DOI: 10.1016/j.thromres.2014.01.011. View

10.

Yu J, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz J . Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2004; 105(4):1734-41. DOI: 10.1182/blood-2004-05-2042. View

11.

Bowbrick V, Mikhailidis D, Stansby G . The use of citrated whole blood in thromboelastography. Anesth Analg. 2000; 90(5):1086-8. DOI: 10.1097/00000539-200005000-00015. View

12.

Kristinsson S, Fears T, Gridley G, Turesson I, Mellqvist U, Bjorkholm M . Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008; 112(9):3582-6. PMC: 2572787. DOI: 10.1182/blood-2008-04-151076. View

13.

Kristinsson S . Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2011; 2010:437-44. DOI: 10.1182/asheducation-2010.1.437. View

14.

ODonnell J, Tuddenham E, Manning R, Kemball-Cook G, Johnson D, Laffan M . High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997; 77(5):825-8. View

15.

Bloom A . The biosynthesis of factor VIII. Clin Haematol. 1979; 8(1):53-77. View

16.

Crowley M, Eustace J, OShea S, Gilligan O . Venous thromboembolism in patients with myeloma: incidence and risk factors in a "real-world" population. Clin Appl Thromb Hemost. 2014; 20(6):600-6. DOI: 10.1177/1076029614521280. View

17.

Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G . The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost. 2003; 29(3):275-82. DOI: 10.1055/s-2003-40965. View

18.

Catovsky D, Ikoku N, Pitney W, GALTON D . Thromboembolic complications in myelomatosis. Br Med J. 1970; 3(5720):438-9. PMC: 1701392. DOI: 10.1136/bmj.3.5720.438. View

19.

Gregersen H, Norgaard M, Severinsen M, Engebjerg M, Jensen P, Sorensen H . Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol. 2010; 86(2):129-34. DOI: 10.1111/j.1600-0609.2010.01539.x. View

20.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A . Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2011; 119(4):933-9. DOI: 10.1182/blood-2011-03-344333. View